Kosan BioSciences -- KOSN Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Kosan BioSciences -- KOSN

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who started this subject	4/21/2004 1:05:21 PM
From: scaram(o)uche	of 933

17-Allylamino-17-Demethoxygeldanamycin (17-AAG) abrogates the G2/M cell cycle checkpoint by down-regulating chk1 and selectively sensitizes tumor cells with defective p53 to topoisomerase I poison. Time: Monday, June 07, 2004, 8:00am-12:00pm Presenter: Archie N. Tse, MD, PhD Abstract ID: 3069 Poster Number: N8 Session: Developmental Therapeutics: Molecular Therapeutics Monday, June 07, 2004, 8:00am-12:00pm

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next